Valacyclovir and Sarclisa drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Valacyclovir (valacyclovir hydrochloride) and Sarclisa (isatuximab-irfc). Common drug interactions include rash pruritic among females and neutropenia among males.

The phase IV clinical study analyzes what interactions people have when they take Valacyclovir and Sarclisa. It is created by eHealthMe based on reports of 40 people who take the same drugs from the FDA, and is updated regularly.

What is Valacyclovir?

Valacyclovir has active ingredients of valacyclovir hydrochloride. It is often used in genital herpes. eHealthMe is studying from 42,107 Valacyclovir users. Check the latest studies of Valacyclovir.

What is Sarclisa?

Sarclisa has active ingredients of isatuximab-irfc. eHealthMe is studying from 541 Sarclisa users. Check the latest studies of Sarclisa.



On Jul, 12, 2026

40 people who take Valacyclovir and Sarclisa together, and have interactions are studied.

Valacyclovir and Sarclisa drug interactions.

What are the common drug interactions of Valacyclovir and Sarclisa, by gender? *:

female:

  1. Rash pruritic (redness with itching)
  2. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)
  3. Blood pressure increased
  4. Cholangiocarcinoma (a cancer that forms glands or secretes significant amounts of mucins)
  5. Constipation
  6. Fatigue (feeling of tiredness)
  7. Squamous cell carcinoma of skin (a cancer of a kind of epithelial cell, the squamous cell. these cells are the main part of the epidermis of the skin)

male:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Chronic kidney disease
  3. Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
  4. Haematoma (collection of blood outside the blood vessels)
  5. Haemoperitoneum (presence of blood in the peritoneal cavity)
  6. Hepatic failure (liver failure)
  7. Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
  8. Jaundice cholestatic
  9. Leukopenia (less number of white blood cells in blood)
  10. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)

What are the common drug interactions of Valacyclovir and Sarclisa, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Alcohol use
  2. Chest discomfort
  3. Cough
  4. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  5. Flushing (the warm, red condition of human skin)
  6. Hypertension (high blood pressure)
  7. Light chain disease (a rare blood cell disease which is characterized by deposition of fragments of infection-fighting immunoglobulins)
  8. Nausea (feeling of having an urge to vomit)
  9. Osteoarthritis (a joint disease caused by cartilage loss in a joint)
  10. Rash maculo-papular (red area on the skin that is covered with small confluent bumps)

60+:

  1. Neutropenia (an abnormally low number of neutrophils)
  2. Chronic kidney disease
  3. Febrile bone marrow aplasia (bone marrow greatly decreases or stops production of blood cells)
  4. Haematoma (collection of blood outside the blood vessels)
  5. Haemoperitoneum (presence of blood in the peritoneal cavity)
  6. Hepatic failure (liver failure)
  7. Hepatitis fulminant (life-threatening condition defined by significantly impaired liver function)
  8. Jaundice cholestatic
  9. Leukopenia (less number of white blood cells in blood)
  10. Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)

What are the existing conditions these people have? *

  1. Multiple Myeloma (cancer of the plasma cells): 40 people, 100.00%
  2. High Blood Pressure: 13 people, 32.50%
  3. Type 2 Diabetes: 9 people, 22.50%
  4. Neuralgia (pain in one or more nerves): 7 people, 17.50%
  5. Fever: 4 people, 10.00%
  6. Arthritis (form of joint disorder that involves inflammation of one or more joints): 4 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Valacyclovir and Sarclisa?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Valacyclovir and Sarclisa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Valacyclovir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Sarclisa:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Valacyclovir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sarclisa and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on valacyclovir hydrochloride and isatuximab-irfc (the active ingredients of Valacyclovir and Sarclisa, respectively), and Valacyclovir and Sarclisa (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: